Please login to the form below

Not currently logged in
Email:
Password:

psychiatric diseases

This page shows the latest psychiatric diseases news and features for those working in and with pharma, biotech and healthcare.

Merck and Cerevance to research novel targets in Alzheimer’s disease

Merck and Cerevance to research novel targets in Alzheimer’s disease

Cerevance, a specialist in diseases affecting the central nervous system (CNS), plans to concurrently out-license the programme according to the terms of the agreement with Merck. ... Human brain tissue evaluations such as these can reveal biological

Latest news

  • Novartis plans digital therapeutics for schizophrenia and MS Novartis plans digital therapeutics for schizophrenia and MS

    Jay Bradner, president of the Novartis Institutes for Biomedical Research, said: "Psychiatric and neurodegenerative diseases place a heavy physical, mental and economic burden on patients and their families. ... With widespread adoption of digital devices

  • Boehringer crowdsources psychiatric research team Boehringer crowdsources psychiatric research team

    The team of neuroscientists was identified by Boehringer and BioMed X via a crowdsourcing competition tasked with exploring the 'most promising solution approaches' to psychiatric diseases. ... Last year, Boehringer Ingelheim entered into a psychiatric

  • Boehringer pledges €11bn to fund R&D drive Boehringer pledges €11bn to fund R&D drive

    All four collaborations are focusing on research into inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, looking at new therapeutic targets as well as biomarkers that can be ... In addition, the company signed a deal with Circuit

  • John Thievon named president of Dey Pharma

    As president of Dey Pharma, Thievon will drive the company's focus on medicines to treat respiratory diseases, severe allergic reactions and psychiatric disorders.

  • GSK/Neurocrine depression drug fails

    Neurocrine and GSK signed a worldwide research, development and commercialisation agreement for Corticotropin Releasing Factor Receptor Antagonists for psychiatric, neurological and gastrointestinal diseases in 2001.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • The role of digital health technology tools in supporting medical adherence The role of digital health technology tools in supporting medical adherence

    Approximately 50% of patients with chronic diseases requiring maintenance self-medications do not take them in a prescribed way. ... Illness factors (psychiatric diseases and dementias). Disruption of lifestyle, limited autonomy.

  • Deal Watch January 2016 Deal Watch January 2016

    Product portfolio covering rare diseases in haematology, immunology, oncology; cash and stock deal at 37.5% share price premium. ... 280. Arena / Boehringer Ingelheim. Joint research collaboration. Development of treatments for psychiatric diseases and

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Sanofi appoints Diane Souza and Thomas Südhof Sanofi appoints Diane Souza and Thomas Südhof

    Before joining Stanford, he spent 25 years at the University of Texas as chairman of the department of neuroscience researching neuro-degenerative and neuro-psychiatric diseases.

  • MedDay appoints former Sanofi VP to board MedDay appoints former Sanofi VP to board

    Goupit said: “I strongly believe that MedDay's product pipeline and its research platform, SPECMET, could have a major impact on the treatment of neurological and psychiatric diseases.”.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Diagnosing the lag in neuropsychiatric treatments

    This means that while successful drugs for psychiatric diseases have been introduced into the market, subsequent new drugs are based on similar mechanisms of actions or therapeutic targets. ... The answer is simple, while bacterial and viral infections

  • emotive. expands Medical Writing and Client Services teams

    With over 9 years’ experience in medical communications, Aki Okazaki who is joining as an Associate Director, has worked in a broad range of therapeutic areas including haematology, infectious diseases, oncology, ... psychiatric conditions, rare

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....
Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...